PROTHENA CORP PUBLIC LTD CO
PRTANasdaq
$8.66
↑ +2.2%Jul 17 close · end-of-day
Price
1Y↑ +37.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$468.6M
Enterprise Value
$139.1M
P/E
—
P/S
8.1
P/B
1.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$57.9M
Net Income (TTM)
-$151.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-205.4%
Net Margin
-260.9%
ROE
-48.4%
ROIC
—
Debt / Equity
—
Net Cash
$329.5M
Return 1Y
+33.9%
Company profile
Prothena Corporation plc focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, is in clinical trials for Parkinson's disease; PRX004, which completed Phase I clinical trial.
- CEO
- Gene G. Kinney
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 130
- Website
- prothena.com
Management & directors
- Kinney Gene G.President and CEO
- Malecek Michael JChief Legal Officer
- Nguyen TranChief Strategy Officer and CFO
- Smith Brandon S.Chief Operating Officer
- Swanson Chad J.Chief Development Officer
- Walker Karin LChief Accounting Officer
- Zago Wagner M.Chief Scientific Officer
Roles derived from SEC Form 4 filings.
Earnings
PRTA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$51.1M↑ +1706.4%
Diluted EPS$0.60↓ -153.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $853,000.00 | $200.6M | $53.9M | $91.4M | $135.2M | $9.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$112.7M | $72.0M | -$131.6M | -$191.0M | -$154.6M | -$214.6M |
| Net income | -$111.1M | $67.0M | -$116.9M | -$147.0M | -$122.3M | -$244.1M |
| Diluted EPS | -$2.78 | $1.38 | -$2.47 | -$2.76 | -$2.27 | -$4.53 |
| Operating cash flow | -$80.4M | $92.6M | -$108.8M | -$133.9M | -$150.1M | -$163.6M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -13216.2% | 35.9% | -244.1% | -209.1% | -114.4% | -2216.4% |
| Net margin | -13029.8% | 33.4% | -217.0% | -160.9% | -90.5% | -2520.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $132.0M | $970,000.00 | $2.1M | $2.8M | $4.4M | $2.4M | $21,000.00 | $51.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $58.4M | -$66.5M | -$64.9M | -$65.6M | -$84.6M | -$40.2M | -$24.2M | $30.0M |
| Net income | $66.9M | -$59.0M | -$58.0M | -$60.2M | -$125.8M | -$36.5M | -$21.6M | $32.7M |
| Diluted EPS | $1.22 | -$1.10 | -$1.05 | -$1.12 | -$2.34 | -$0.68 | -$0.39 | $0.60 |
| Operating cash flow | $16.0M | -$45.2M | -$47.8M | -$53.4M | -$46.3M | -$40.6M | -$23.3M | $28.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 44.2% | -6857.0% | -3056.9% | -2319.0% | -1914.4% | -1666.3% | -115252.4% | 58.8% |
| Net margin | 50.7% | -6082.6% | -2729.9% | -2128.5% | -2845.4% | -1513.1% | -102804.8% | 64.1% |
Company news
Jun 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-16 | SCULLY WILLIAM P | Buy | 20,000 | $7.90 | $157,990.00 | filing |
| 2026-06-15 | SCULLY WILLIAM P | Gift | 325,000 | $0.00 | $0.00 | filing |
| 2026-06-11 | SCULLY WILLIAM P | Buy | 125,000 | $8.17 | $1.0M | filing |
| 2026-06-04 | SCULLY WILLIAM P | Buy | 50,000 | $9.31 | $465,295.00 | filing |
| 2026-06-02 | SCULLY WILLIAM P | Buy | 50,000 | $9.43 | $471,300.00 | filing |
| 2026-05-22 | SCULLY WILLIAM P | Buy | 100,000 | $9.81 | $981,300.00 | filing |
| 2025-07-28 | Zago Wagner M.· Chief Scientific Officer | Award | 85,000 | $0.00 | $0.00 | filing |
| 2025-07-28 | Walker Karin L· Chief Accounting Officer | Award | 25,000 | $0.00 | $0.00 | filing |
| 2025-07-28 | Swanson Chad J.· Chief Development Officer | Award | 85,000 | $0.00 | $0.00 | filing |
| 2025-07-28 | Smith Brandon S.· Chief Operating Officer | Award | 130,000 | $0.00 | $0.00 | filing |
| 2025-07-28 | Nguyen Tran· Chief Strategy Officer and CFO | Award | 95,000 | $0.00 | $0.00 | filing |
| 2025-07-28 | Malecek Michael J· Chief Legal Officer | Award | 80,000 | $0.00 | $0.00 | filing |
| 2025-07-28 | Kinney Gene G.· President and CEO | Award | 140,000 | $0.00 | $0.00 | filing |
Latest 13 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.